NORTHSTAR DISTRIBUTION CENTER 8912 supplier risk profile Q1 2026—27 suppliers, India-focused pharma sourcing, B-grade risk score.
NORTHSTAR DISTRIBUTION CENTER 8912 processed 165 shipments in Q1 2026 across 27 suppliers in 4 countries. India dominated the sourcing footprint with 144 shipments (87.3% of total volume), driven primarily by pharmaceutical manufacturers including Aurobindo Pharma (33 shipments), Macleods Pharmaceuticals Godown (17), and Zydus Lifesciences (15). The import activity centers on HS Chapter 30 (pharmaceutical products), with secondary exposure to Chapter 30 subheadings 300490 and 300420. Extended supplier visibility extends to 26 tier-2 and 43 tier-3 entities in the sourcing network.
Distance-screened against all 380 facilities in the ASPI Xinjiang Data Project. Proximity score: 100 / 100.
One name on the importer's shipment records registered a match against sanctions watchlists. No suppliers in the active supply chain show documented exposure under the Uyghur Forced Labor Prevention Act (UFLPA) or similar forced-labor proximity indicators.
27 distinct tier-1 suppliers in Q1 2026
| AUROBINDO PHARMA | India | 33 |
| MACLEODS PHARMACEUTICALS GODOWN | India | 17 |
| ZYDUS LIFESCIENCES | India | 15 |
| AVET LIFESCIENCES PRIVATE | India | 12 |
| INDOCO REMEDIES | India | 11 |
| DR REDDY S LABORATORIES | India | 11 |
| ANNORA PHARMA PRIVATE | India | 10 |
| HETERO LABS | India | 9 |
Share of Q1 2026 inbound shipments by source country
26 tier-2 + 43 tier-3 nodes mapped - sign up to see them.
Free Tarifflo account unlocks the complete tier 1 / 2 / 3 supplier graph, daily refresh, alerts, and sanctions + UFLPA monitoring on every shipment.